252 related articles for article (PubMed ID: 30608986)
1. The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review.
Mac S; da Silva SR; Sander B
PLoS One; 2019; 14(1):e0210280. PubMed ID: 30608986
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic outcomes evaluated in Lyme disease: a systematic review.
Mattingly TJ; Shere-Wolfe K
Parasit Vectors; 2020 Jul; 13(1):341. PubMed ID: 32646476
[TBL] [Abstract][Full Text] [Related]
4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
5. A cost-of-illness study of Lyme disease in the United States.
Maes E; Lecomte P; Ray N
Clin Ther; 1998; 20(5):993-1008; discussion 992. PubMed ID: 9829450
[TBL] [Abstract][Full Text] [Related]
6. Estimating direct healthcare costs attributable to laboratory-confirmed Lyme disease in Ontario, Canada: A population-based matched cohort study using health administrative data.
Shing E; Wang J; Khoo E; Evans GA; Moore S; Nelder MP; Patel SN; Russell C; Sider D; Sander B
Zoonoses Public Health; 2019 Jun; 66(4):428-435. PubMed ID: 30665259
[TBL] [Abstract][Full Text] [Related]
7. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.
Koltai M; Moyes J; Nyawanda B; Nyiro J; Munywoki PK; Tempia S; Li X; Antillon M; Bilcke J; Flasche S; Beutels P; Nokes DJ; Cohen C; Jit M
BMC Med; 2023 Mar; 21(1):120. PubMed ID: 37004062
[TBL] [Abstract][Full Text] [Related]
8. Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review.
Franklin M; Pollard D; Sah J; Rayner A; Sun Y; Dube F; Sutton A; Qin L
Adv Ther; 2024 Jul; 41(7):2700-2722. PubMed ID: 38833143
[TBL] [Abstract][Full Text] [Related]
9. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of the Lyme disease vaccine.
Hsia EC; Chung JB; Schwartz JS; Albert DA
Arthritis Rheum; 2002 Jun; 46(6):1651-60. PubMed ID: 12115198
[TBL] [Abstract][Full Text] [Related]
11. Methodological considerations in the assessment of direct and indirect costs of back pain: A systematic scoping review.
Zemedikun DT; Kigozi J; Wynne-Jones G; Guariglia A; Roberts T
PLoS One; 2021; 16(5):e0251406. PubMed ID: 33974661
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of vaccination against Lyme disease.
Shadick NA; Liang MH; Phillips CB; Fossel K; Kuntz KM
Arch Intern Med; 2001 Feb; 161(4):554-61. PubMed ID: 11252114
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL
Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866
[TBL] [Abstract][Full Text] [Related]
14. Healthcare claims-based Lyme disease case-finding algorithms in the United States: A systematic literature review.
Nam YH; Willis SJ; Mendelsohn AB; Forrow S; Gessner BD; Stark JH; Brown JS; Pugh S
PLoS One; 2022; 17(10):e0276299. PubMed ID: 36301959
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis of delivering primary health care services through community health workers in 3 North Indian states.
Prinja S; Jeet G; Verma R; Kumar D; Bahuguna P; Kaur M; Kumar R
PLoS One; 2014; 9(3):e91781. PubMed ID: 24626285
[TBL] [Abstract][Full Text] [Related]
16. Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014-2016.
Hook SA; Jeon S; Niesobecki SA; Hansen AP; Meek JI; Bjork JKH; Dorr FM; Rutz HJ; Feldman KA; White JL; Backenson PB; Shankar MB; Meltzer MI; Hinckley AF
Emerg Infect Dis; 2022 Jun; 28(6):1170-1179. PubMed ID: 35608612
[TBL] [Abstract][Full Text] [Related]
17. Tobacco Cost of Illness Studies: A Systematic Review.
Makate M; Whetton S; Tait RJ; Dey T; Scollo M; Banks E; Norman R; Pidd K; Roche AM; Allsop S
Nicotine Tob Res; 2020 Apr; 22(4):458-465. PubMed ID: 30874290
[TBL] [Abstract][Full Text] [Related]
18. Cost of adult chronic rhinosinusitis: A systematic review.
Smith KA; Orlandi RR; Rudmik L
Laryngoscope; 2015 Jul; 125(7):1547-56. PubMed ID: 25640115
[TBL] [Abstract][Full Text] [Related]
19. The health and economic impact and cost effectiveness of interventions for the prevention and control of overweight and obesity in Kenya: a stakeholder engaged modelling study.
Wanjau MN; Kivuti-Bitok LW; Aminde LN; Veerman JL
Cost Eff Resour Alloc; 2023 Sep; 21(1):69. PubMed ID: 37735408
[TBL] [Abstract][Full Text] [Related]
20. A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies.
Wong AW; Koo J; Ryerson CJ; Sadatsafavi M; Chen W
BMC Pulm Med; 2022 Apr; 22(1):148. PubMed ID: 35443657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
